Three names come up constantly in the weight-loss conversation. Semaglutide. Tirzepatide. Retatrutide. People talk about them like they are the same thing. They are not. Here is the plain version.
Semaglutide works on one receptor. Tirzepatide works on two. Retatrutide works on three. As you add targets, the average weight loss in trials tends to go up. That is the whole pattern in three lines.
FDA-approved. You know it as Ozempic, Wegovy, and Rybelsus. In obesity trials it produced about 15% average weight loss. One large trial also showed it lowered heart risk. A lot of people find it the easier one on the stomach. Full profile here.
FDA-approved. Sold as Mounjaro and Zepbound. It hits two receptors and produced around 20% average weight loss in trials. It is also approved for sleep apnea in people with obesity. It is often stronger than semaglutide, and sometimes harder on the gut. Full profile here.
Not approved yet. It hits three receptors, and Phase 3 trials show about 28% average weight loss, the highest of the group. Eli Lilly is expected to file with the FDA around late 2026 or early 2027. Anything sold as retatrutide today is unapproved and unregulated. Full profile here.
They share a family of side effects. Nausea and other stomach problems, worst while the dose is going up.
They share a catch too. The weight tends to come back if you stop and do not keep the new habits.
And two of the three are real prescriptions. The gray-market vials people buy online are not the same product as the approved drugs.
That is the wrong question for a website to answer. The honest answer is that it depends on your health, your goals, and what your doctor says. This is a walk-in-informed-and-ask situation, not a pick-from-a-website one.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.